An FDA panel has highlighted a concerning decline in testosterone levels among men and is calling for a significant overhaul of the current regulations surrounding testosterone replacement therapy (TRT). The panel recommends that restrictions be eased to make TRT more accessible, stating that the existing regulations are outdated. Experts, including Mohit Khera, MD, shared key takeaways from the discussions, emphasizing the need for updated labeling and increased availability of testosterone therapies for those affected. The FDA is opening the door for potential revisions in testosterone labeling to better address the health crisis related to declining testosterone levels in cisgender men.